

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 8, 2019
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 8, 2019.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD
Philip Mubarak, MD
Gregory Browning, MD
Tan Platt, MD
Cheryl Hartvigsen, RPh

Edward Behling, MD
Duncan Norton, MD
Kelli Savia, MD
Kimberly Rudd, MD

Joni Bolinger, MD
Erika Tillery, PharmD
Kenric Ware, PharmD
Kashyap Patel, MD

SC DHHS Staff:

Jim Bradford, MD
Bryan Amick, PharmD
William Wynn, PharmD
Byron Roberts, JD
Janet Giles
Patricia Witherspoon, MD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, March 6, 2019

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class

+ No speakers

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Class for Re-Review

- Neuropathic Pain (Oral)
- Nasal Antihistamines
- Attention Deficit Hyperactivity Disorder Agents
- Anticholinergic: Respiratory (COPD)
- Xanthine Oxidase Inhibitors (Antihyperuricemics, Oral)
- Antibiotics/Anti-Infectives, GI (Oral)
- Liptropics, Other: Cholesterol Absorption Inhibitors/Fibric Acid Derivatives

The chart below represents the recommendations from the P & T Committee:

NEUROPATHIC PAIN (ORAL)	
Preferred	Non-Preferred
Duloxetine‡ Gabapentin Lyrica (pregabalin)	Cymbalta (duloxetine) Gralise (gabapentin) Horizant (gabapentin enacarbil) Duloxetine DR (Irenka) Savella (milnacipran)+ Lyrica CR (pregabalin ER) Neurontin (gabapentin) Nucynta ER (tapentadol ER)
NASAL ANTIHISTAMINES	
Preferred	Non-Preferred
Azelastine	Astelin/Astepro+ Patanase
ATTENTION DEFICIT HYPERACTIVITY DISORDER	
Preferred	Non-Preferred
Mixed Amphetamine Salts IR/ER‡ Atomoxetine Clonidine ER Dyanavel XR‡ Dexmethylphenidate IR	Adenzys ER/XR ODT Adderall IR/XR+ Aptensio XR Concerta Cotempla XR ODT

ATTENTION DEFICIT HYPERACTIVITY DISORDER (continued)	
Preferred	Non-Preferred
Dextroamphetamine	Daytrana Patch
Focalin XR	Desoxyn
Guanfacine ER	Dexedrine/Dextrostat
Methylphenidate LA/SR	Evekeo
Methylphenidate	Focalin
Methylphenidate ER/CD	Lisdexamfetamine dimesylate
Quillivant/Quilli chew‡	Intuniv
Vyvanse Caps/Chew	Methylin/Metadate ER
	Mydayis
	Nuvigil
	Procentra
	Provigil
	Ritalin SR
	Strattera
	Zenzedi
ANTICHOLINERGICS: RESPIRATORY (COPD) INHALATIONS	
Preferred	Non-Preferred
Atrovent HFA	Anoro Ellipta
Bevespi Aerosphere‡	Incruse Ellipta
Combivent Respimat‡	Lonhala Magnair
Spiriva Handihaler	Seebri Neohaler
Stiolto Respimat	Spiriva Respimat
	Trelegy Ellipta
	Tudorza Pressair
	Utibron Neohaler
	Yupelri
XANTHINE OXIDASE INHIBITORS (ANTIHYPURICEMICS, ORAL)	
Preferred	Non-Preferred
Allopurinol	Colchicine+
Mitigare‡	Duzallo
Probenecid	Uloric
Probenecid/colchicine	Zyloprim
	Zurampic
ANTIBIOTICS/ANTI-INFECTIVES, GI (ORAL)	
Preferred	Non-Preferred
Metronidazole IR	Alinia
Firvanq‡	Dificid
Vancomycin‡	Flagyl ER
	Neomycin tab
	Paromomycin cap
	Solosec
	Tindamax
	Xifaxin
	Vancocin

LIPOTROPICS, OTHER: FIBRIC ACID DERIVATIVES	
Preferred	Non-Preferred
Fenofibrate	Antara, Lofibra
Gemfibrozil	Fibrocor/Fenoglide/Lipofen/Tricor/Triglide
	Lopid
	Trilipix+
LIPOTROPICS, OTHER: CHOLESTEROL ABSORPTION INHIBITORS	
Preferred	Non-Preferred
Zetia‡	

‡ Indicates “Added as Preferred”

+ Indicates “Moved to Non-Preferred”

5. Old Business

None

6. New Business

Bryan provided an updated on the “Community Engagement Waiver”(Sec 1115 Demo Waiver). SC DHHS is currently updating their application and certain groups such as those who are disabled, primary care givers, children and pregnant woman will be excluded from the work requirement. Bryan also advised the Committee of the planned merger between Absolute Total Care (Centene) and Wellcare which is planned for early 2020. The P&T Committee Members introduced themselves. Lisa provided an overview of new drugs to market.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Class for Re-Review

Neuropathic Pain (Oral)

Nasal Antihistamines

Attention Deficit Hyperactivity Disorder Agents

Anticholinergic: Respiratory (COPD)

Xanthine Oxidase Inhibitors (Antihyperuricemics, Oral)

Antibiotics/Anti-Infectives, GI (Oral)

Lipotropics, Other: Cholesterol Absorption Inhibitors/Fibric Acid Derivatives

8. Closing Comments

The next meeting will be held on Wednesday, August 7, 2019.

9. Adjournment

The meeting adjourned at 5:46 p.m.